
    
      A multicentre, open-label, randomized, Phase 2 study to evaluate the efficacy and safety of
      treatment with MYOCETÂ® in combination with cyclophosphamide and trastuzumab versus free
      doxorubicin in combination with cyclophosphamide, each followed by docetaxel and trastuzumab,
      in women with stage II or III breast cancer whose tumour overexpresses the HER2 gene.
    
  